Stocktoria
YD Bio Ltd YDES
Nasdaq · stock · Services-Medical Laboratories · website · IPO 2025-08-29
YD Bio Ltd financials (annual)
Bars are annual figures from 2024 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | $596,817 | $510,360 |
| Gross profit | $167,410 | $155,356 |
| R&D expense | $1.6M | $491,353 |
| Operating income | -$5.3M | -$1.5M |
| Income tax | -$1,531 | $25,080 |
| Net income | -$8.3M | -$1.4M |
| EPS (diluted) | $-0.12 | $-0.02 |
| Operating cash flow | -$6.6M | -$1.2M |
| Free cash flow | -$8.0M | -$1.3M |
| Cash & equivalents | $6.0M | $3.1M |
| Inventory | $1.9M | $37,335 |
| Total assets | $13.8M | $6.9M |
| Total liabilities | $16.6M | $273,980 |
| Shareholders' equity | -$2.9M | $6.6M |
Growth · year-over-year · Revenue CAGR 16.9%
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue growth | +16.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.